Claritin-D 24 hour
Selected indexed studies
- The risk of esophageal obstruction associated with an anti-allergy medication (Claritin-D 24-Hour--original formulation). (Pharmacoepidemiol Drug Saf, 2004) [PMID:14971120]
- Upper gastrointestinal obstruction associated with Claritin-D 24 Hour Extended Release tablets. (J Allergy Clin Immunol, 1997) [PMID:9314359]
- Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis. (Am J Ther, 1998) [PMID:10099066]
_Worker-drafted node — pending editorial review._
Connections
Claritin-D 24 hour is a side effect of
Sources
- Desloratadine: an update of its efficacy in the management of allergic disorders. (2003) pubmed
- The risk of esophageal obstruction associated with an anti-allergy medication (Claritin-D 24-Hour--original formulation). (2004) pubmed
- Safety and tolerability of treatments for allergic rhinitis in children. (2004) pubmed
- Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis. (1998) pubmed
- Clinical pharmacology of new histamine H1 receptor antagonists. (1999) pubmed
- Translating the evidence on atypical depression into clinical practice. (2007) pubmed
- Esophageal retention of loratadine plus pseudoephedrine extended-release tablets (Claritin-D 24 Hour). (1998) pubmed
- Upper gastrointestinal obstruction associated with Claritin-D 24 Hour Extended Release tablets. (1997) pubmed
- 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. (2002) pubmed
- Effect of desloratadine on the control of morning symptoms in patients with seasonal and perennial allergic rhinitis. (2006) pubmed